India Ophthalmology Devices Market Analysis by Mordor Intelligence
The Indian ophthalmic devices market size is valued at USD 1.49 billion in 2024 and is forecast to reach USD 2.21 billion by 2030, advancing at a 6.91% CAGR between 2025 and 2030. Robust public‐health funding, rising digital‐screen exposure, and a widening pool of older adults are aligning to create a broad, stable demand base that shields the Indian ophthalmic devices market from short-term economic swings. The National Programme for Prevention and Control of Blindness (NPCB) and the Ayushman Bharat Health Infrastructure Fund (AB-HIF) together underwrite large‐scale device procurements, while private hospitals and ambulatory surgery centres chase premium technologies to attract urban patients. Indigenous start-ups now introduce frugal innovations that undercut traditional import prices by up to 50%, prompting global brand owners to localise production and re-engineer mid-tier platforms for the Indian ophthalmic devices market. Competitive intensity is pivoting from pure hardware credentials to service uptime, clinician training, and digital connectivity, signalling a maturity arc that historically took longer to unfold in comparable emerging markets.
Key Report Takeaways
- By device type, vision care devices led with 63.71% Indian ophthalmic devices market share in 2024, whereas diagnostic & monitoring devices are projected to expand at a 9.03% CAGR through 2030.
- By disease indication, cataract solutions captured 39.61% share of the Indian ophthalmic devices market size in 2024, while diabetic-retinopathy products are positioned to grow at an 8.20% CAGR to 2030.
- By end-user, hospitals accounted for 45.91% of the Indian ophthalmic devices market size in 2024; ambulatory surgery centres are expected to post the fastest 8.05% CAGR during 2025-2030.
India Ophthalmology Devices Market Trends and Insights
Driver Impact Analysis
Driver | % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
---|---|---|---|
National Program for Prevention & Control of Blindness (NPCB) catalysing state-level device procurements | +1.2 | National, with emphasis on underserved states | Medium term (2-4 years) |
Expansion of Ayushman Bharat Health Infrastructure Fund driving ophthalmic OT upgrades | +0.9 | National, strongest in Tier-II/III cities | Medium term (2-4 years) |
Rapid uptake of femtosecond-laser-assisted cataract surgery (FLACS) in Tier-I cities | +0.7 | Metropolitan and Tier-I cities | Short term (≤ 2 years) |
Surge in screen-induced myopia among 6–18-year-olds boosting prescription spectacles | +1.1 | Urban centres, especially South & West India | Long term (≥ 4 years) |
Growing penetration of CSR-funded mobile eye-surgery camps in rural West India | +0.6 | Rural West India, expanding to Central & East | Medium term (2-4 years) |
Emergence of indigenous low-cost OCT & fundus cameras from start-ups (e.g., Remidio) | +0.8 | National, early adoption in South India | Medium term (2-4 years |
Source: Mordor Intelligence
National Programme for Prevention and Control of Blindness Catalysing State-level Device Procurements
The NPCB earmarked INR 2 506.9 crore for district eye-care projects in the current plan cycle, and tenders now prioritise portable slit lamps, handheld fundus cameras, and modular phaco machines for secondary facilities[1]Bhopal Memorial Hospital & Research Centre, “NPCB Budget Allocation,” bmhrc.ac.in. States that deploy mobile ophthalmic units report shorter referral times, nudging private vendors to embed battery back-up and rugged casings in product designs. The funding stream also mandates training quotas, so manufacturers that bundle onsite workshops gain a competitive edge. Ultimately, steady NPCB financing shores up baseline demand across the Indian ophthalmic devices market, creating visibility that helps suppliers justify local assembly lines.
Ayushman Bharat Health Infrastructure Fund Driving Ophthalmic OT Upgrades
The Union budget allocates more than INR 90 000 crore for AB-HIF in 2025, releasing capital to modernise operating theatres in 12 000 public hospitals[2]Ministry of Health & Family Welfare, “Ayushman Bharat Health Infrastructure Fund Brief,” mohfw.gov.in. Ophthalmology departments are utilising these grants to install networked microscopes, sterilisation pods, and environment-control systems that reduce postoperative infection rates. Interoperable software integrates the new hardware with the Ayushman Bharat Digital Mission, providing asset-usage analytics that influence future procurement models. When utilisation rates become transparent, administrators favour platforms with documented uptime histories, pushing global and domestic vendors to deliver verified service metrics to protect Indian ophthalmic devices market share.
Rapid Uptake of Femtosecond Laser-Assisted Cataract Surgery in Tier-I Cities
Metropolitan eye chains are marketing Femtosecond Laser-Assisted Cataract Surgery (FLACS) as a gentler alternative to conventional phacoemulsification, even though it adds roughly INR 70 000 to a cataract bill. Surgeons highlight sub-2 mm incisions and faster visual recovery to position FLACS as a premium bundle with toric or multifocal intraocular lenses. As patients upgrade, disposable accessory consumption rises, amplifying recurring revenue. Vendors that provide integrated laser, imaging, and IOL suites find stronger bargaining power with top chains, contributing to the demand slope that lifts the Indian ophthalmic devices market.
Surge in Screen-Induced Myopia Among 6–18 Year-olds Boosting Prescription Spectacles
Screen time among urban students often exceeds 6 hours a day, and researchers project paediatric myopia prevalence could reach 48.1% by 2050[3]Times of India, “Urban Screen Time and Myopia,” timesofindia.indiatimes.com. Parents now seek earlier eye exams, swelling footfall at optical outlets and driving adoption of handheld autorefractors for on-site refraction. Blue-light filtering and anti-fatigue lenses become standard upsell features, reinforcing Vision Care Devices as the economic anchor of the Indian ophthalmic devices market.
Restraints Impact Analysis
Restraints Impact Analysis | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
---|---|---|---|
Shortage of trained vitreo-retinal surgeons in Tier-II/III cities | –0.8 | Tier-II/III cities, Central & East India | Medium term (2-4 years) |
High 12% GST on ophthalmic capital equipment raising cap-ex barriers for small clinics | –0.6 | National, felt most in smaller cities | Short term (≤ 2 years) |
Price-sensitive consumer base limiting adoption of daily-disposable contact lenses | –0.4 | National, stronger in rural areas | Long term (≥ 4 years) |
Fragmented after-sales service network outside metro clusters | –0.5 | Semi-urban & rural regions nationwide | Medium term (2-4 years) |
Source: Mordor Intelligence
Shortage of Trained Vitreo-Retinal Surgeons in Tier-II/III Cities
India has about 1 400 registered retinal specialists for more than 1.4 billion citizens, leaving many districts without adequate surgical coverage. Hospitals hesitate to invest in advanced vitrectomy consoles when qualified staff remain scarce, muting high-end device demand outside metros. Equipment makers respond with intuitive graphical interfaces and remote-support modules, yet real expansion awaits residency pipeline reforms. Until then, the talent deficit slows penetration of complex systems in large pockets of the Indian ophthalmic devices market.
High GST on Ophthalmic Capital Equipment Raising Cap-ex Barriers for Small Clinics
Ophthalmic capital goods still attract a 12% Goods and Services Tax, unlike ostomy appliances that were lowered to 5% in 2024. For single-chair clinics, the tax adds meaningful strain to cash flows because input-credit eligibility is unclear, pushing many owners to defer purchases. Larger hospital chains leverage volume discounts and financing deals to blunt the impact, widening the competitive gulf. Unless future GST Council rulings reduce the rate, small practices will struggle to refresh fleets, affecting overall velocity in the Indian ophthalmic devices market.
Segment Analysis
By Device Type: Vision Care Dominance and Diagnostic Acceleration
Vision Care Devices, ranging from frames to automated lens edging systems, held 63.71% Indian ophthalmic devices market share in 2024. The rise of organised retail chains and corporate wellness programmes drives demand for quick refraction tools and lens-coating units that allow same-visit dispensing. Parallel e-commerce platforms funnel online shoppers into stores for final fittings, boosting traffic for objective refraction kiosks. AI-enabled lens-measurement apps further compress consultation times, increasing throughput without large capital spend.
Diagnostic & Monitoring Devices are on track for a 9.03% CAGR because portable OCT scanners, smartphone-linked fundus cameras, and home tonometry kits blend affordability with clinical precision. Regulatory acceptance of offline AI, illustrated by the CDSCO nod to Remidio’s Medios DR AI in 2024, enhances clinician confidence. Investment flows into cloud platforms that analyse imaging data, trading upfront hardware margins for subscription revenues. Surgical Devices remain smaller but capture high-value spend as FLACS and microincision vitrectomy units replace legacy phaco systems in referral hospitals. Suppliers leverage service contracts that guarantee 95% uptime, embedding loyalty and recurring part sales into the Indian ophthalmic devices market size calculus.
Note: Segment shares of all individual segments available upon report purchase
By Disease Indication: Cataract Volume and Diabetic Retinopathy Velocity
Cataract equipment retains the largest slice of Indian ophthalmic devices market size at 39.61% because public hospitals must meet surgery targets set under NPCB. High-volume district centres prefer dual-phaco workstations that permit parallel cases, lifting daily throughput. Disposable injector systems and foldable intraocular lenses account for the bulk of consumable spend, sustaining manufacturer service footprints in semi-urban belts.
Diabetic retinopathy solutions promise an 8.20% CAGR as India hosts more than 101 million diabetics. Early-stage screening now migrates into primary clinics and mobile vans, empowering non-ophthalmologists to capture retinal images. AI algorithms triage cases by severity, freeing scarce specialists for complex interventions. Glaucoma and age-related macular degeneration segments follow behind yet harvest incremental demand through minimally invasive implants and sustained-release drug dispensers, nudging cross-selling opportunities across the Indian ophthalmic devices market.
Note: Segment shares of all individual segments available upon report purchase
By End-user: Hospital Scale Meets ASC Agility
Hospitals captured 45.91% of the Indian ophthalmic devices market size in 2024, driven by their capacity to host complex multi-specialty clinics and obtain AB-HIF grants for operating-theatre upgrades. Digital imaging suites link operating rooms to teaching auditoriums, reinforcing hospitals’ role as talent hubs and service referral nodes. Specialty ophthalmic clinics place second; their nimble governance lets them trial AI triage tools sooner, expanding patient rosters without proportionate staff additions.
Ambulatory surgery centres log an expected 8.05% CAGR because insurers push for procedures that qualify for same-day discharge, cutting cost per case by up to 40%. Vendors respond with compact phaco machines and integrated sterilisation modules that fit space-constrained venues. Mobile eye units, often CSR funded, operate hub-and-spoke circuits that serve migration corridors, embedding rugged devices into rural delivery models across the Indian ophthalmic devices market.
Geography Analysis
Metropolitan clusters such as Mumbai, Bengaluru, Delhi-NCR, and Chennai collectively anchor more than half of Indian ophthalmic devices market revenue. These cities enjoy deeper insurance penetration, larger pools of ophthalmologists, and a consumer base willing to upgrade to premium intraocular lenses or pay out-of-pocket for FLACS. Eye-care chains consciously stage flagship centres in such metros to showcase technology, translating into a constant refresh cycle for microscopes, lasers, and diagnostic suites. At the same time, municipal governments run school-screening drives that raise baseline demand for autorefractors and handheld spot vision screeners.
Southern states occupy the innovation front line. Kerala’s Nayanamritham 2.0 programme links peripheral health workers to AI analytics that flag diabetic retinopathy and glaucoma in real time. Tamil Nadu’s long-standing universal health insurance covers cataract surgery at contracted private hospitals, ensuring regular volumes for consumable supply contracts. Startup incubators in Bengaluru and Hyderabad nurture hardware–software hybrids that suit Indian environments, boosting indigenous contribution to the Indian ophthalmic devices market.
Western states like Maharashtra and Gujarat ride corporate social responsibility (CSR) budgets that mobilise surgical buses into tribal districts. Reliance Foundation alone financed more than 545 cataract surgeries in FY 2023 through mobile camps, sustaining off-grid generators, compact anaesthesia carts, and rugged vitrectomy units. Such efforts seed familiarity with modern equipment among rural clinicians, priming future purchase cycles once district hospitals expand.
Northern, Central, and Northeastern regions present the steepest growth gradients. The Ayushman Bharat Digital Mission deploys a unified health-ID system that enables teleophthalmology consults for hill states and flood-prone plains. As road connectivity improves, distributors shorten delivery timelines for fragile items like green laser photocoagulators, making secondary towns viable sales targets. States such as Uttar Pradesh and Assam now ring-fence district budgets for vision-screening vans, creating first-time buyers in the Indian ophthalmic devices market. Over the forecast horizon, the convergence of central funding, telemedicine, and grassroots outreach is expected to flatten adoption disparities, but unique regional device mixes—battery life in arid zones, miniaturisation in hill terrain—will persist.
Competitive Landscape
Global manufacturers such as Alcon, Johnson & Johnson Vision Care, and Carl Zeiss Meditec secure enduring visibility through surgeon-training academies, broad distribution, and multi-modal portfolios. Alcon’s worldwide sales rose 8% in 2023 to USD 9.37 billion, and part of that growth came from customising mid-price phaco platforms for Indian procurement contracts. These incumbents enter value-sensitive tiers by launching compact workstations that share core optics with flagship lines but exclude premium automation, thereby protecting margin while defending their Indian ophthalmic devices market share.
Indigenous contenders, led by Remidio, Sankara Health Innovation, and Forus Health, deliver smartphone-integrated retinal cameras, low-cost OCT units, and AI screening engines that operate offline. Remidio’s Medios DR AI received CDSCO approval in 2024 and the company closed USD 25 million in venture funding, elevating its valuation to USD 67.5 million. Domestic innovation unlocks price points that Tier-III clinics can afford without sacrificing diagnostic accuracy, pulling latent demand into the formal channel. International brands react by exploring licensing or co-manufacturing deals to maintain relevance across the Indian ophthalmic devices market.
Service differentiation gains prominence. Hospital groups demand uptime guarantees above 95% and expect remote diagnostics to resolve minor glitches within 45 minutes. Vendors now house spare-part depots in eight logistics hubs instead of three, slashing turnaround times. Subscription-based maintenance contracts, once optional, become prerequisite for tender eligibility. As refurbishment quality improves, a price band emerges where certified pre-owned systems compete against new low-cost devices, adding complexity to market positioning decisions. By 2030, the combined share of the top five manufacturers is projected to hover near 55%, keeping the Indian ophthalmic devices market in the moderately fragmented zone where both global and local players can thrive.
India Ophthalmology Devices Industry Leaders
-
Johnson & Johnson Vision Care
-
Carl Zeiss Meditec AG
-
Bausch + Lomb Corp.
-
Alcon Inc.
-
EssilorLuxottica SA
- *Disclaimer: Major Players sorted in no particular order

Recent Industry Developments
- May 2025: Remidio received CDSCO approval for AI modules targeting glaucoma and age-related macular degeneration, expanding its regulatory-cleared portfolio.
- April 2025: Dr Mohan’s Diabetes Specialities Center deployed an in-house AI algorithm that flags early retinal lesions during routine diabetes check-ups, raising screening coverage for its 350 000 patient base.
- February 2025: Kerala launched Nayanamritham 2.0, India’s first state-wide AI eye-disease screening network, in partnership with Remidio and state health authorities.
- October 2024: Remidio’s Medios DR AI, an offline diabetic-retinopathy solution, secured CDSCO clearance, permitting nationwide commercial rollout.
India Ophthalmology Devices Market Report Scope
As per the scope of the report, ophthalmic devices are medical devices used in the identification and treatment of ocular defects or deficiencies and eye disorders. The ophthalmic devices are designed for diagnostics, surgical, and vision correction purposes. These devices are continuously gaining increased importance and adoption due to the high prevalence of various ophthalmic diseases, such as glaucoma, cataract, and other vision-related issues. The Indian Ophthalmology Devices market is segmented by Device (Surgical Device, Diagnostic and Monitoring Device, and Vision Care). The report offers the value (in USD million) for the above segments.
By Device Type | Diagnostic & Monitoring Devices | OCT Scanners | |
Fundus & Retinal Cameras | |||
Autorefractors & Keratometers | |||
Corneal Topography Systems | |||
Ultrasound Imaging Systems | |||
Perimeters & Tonometers | |||
Other Diagnostic & Monitoring Devices | |||
Surgical Devices | Cataract Surgical Devices | ||
Vitreoretinal Surgical Devices | |||
Refreactive Surgical Devices | |||
Glaucoma Surgical Devices | |||
Other Surgical Devices | |||
Vision Care Devices | Spectacles Frames & Lenses | ||
Contact Lenses | |||
By Disease Indication | Cataract | ||
Glaucoma | |||
Diabetic Retinopathy | |||
Other Disease Indications | |||
By End-user | Hospitals | ||
Specialty Ophthalmic Clinics | |||
Ambulatory Surgery Centers (ASCs) | |||
Other End-users |
Diagnostic & Monitoring Devices | OCT Scanners |
Fundus & Retinal Cameras | |
Autorefractors & Keratometers | |
Corneal Topography Systems | |
Ultrasound Imaging Systems | |
Perimeters & Tonometers | |
Other Diagnostic & Monitoring Devices | |
Surgical Devices | Cataract Surgical Devices |
Vitreoretinal Surgical Devices | |
Refreactive Surgical Devices | |
Glaucoma Surgical Devices | |
Other Surgical Devices | |
Vision Care Devices | Spectacles Frames & Lenses |
Contact Lenses |
Cataract |
Glaucoma |
Diabetic Retinopathy |
Other Disease Indications |
Hospitals |
Specialty Ophthalmic Clinics |
Ambulatory Surgery Centers (ASCs) |
Other End-users |
Key Questions Answered in the Report
What is the current Indian ophthalmic devices market size?
The market is valued at USD 1.59 billion for 2025.
How fast is the Indian ophthalmic devices industry expected to grow?
A CAGR of 6.91% is forecast for 2025-2030, taking the market to USD 2.21 billion by 2030.
Which device category holds the largest Indian ophthalmic devices market share?
Vision Care Devices lead with 63.71% share in 2024, driven by strong demand for spectacles and contact lenses.
Why are Diagnostic and Monitoring Devices growing rapidly?
AI integration and portable designs enable earlier disease detection, supporting a projected 9.03 % CAGR through 2030.
What regional markets show the highest growth potential?
Northern, Central, and Northeastern states demonstrate high upside due to expanding health infrastructure and tele-ophthalmology programmes.
How are indigenous manufacturers affecting competition?
Local start-ups offer cost-effective, AI-enabled equipment that forces multinational brands to recalibrate pricing and after-sales strategies, reshaping competitive dynamics.
Page last updated on: July 15, 2025